Michael Wang, MD, reviews ASH 2025 data showing durable safety with long-term BTK inhibition, promising next-generation targeted agents, sustained CAR T-cell efficacy, and evidence favoring upfront ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results